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CD74 (invariant MHC class II) regulates protein trafficking and is a receptor for macro-
phage migration inhibitory factor (MIF) and d-dopachrome tautomerase (d-DT/MIF-2). 
CD74 expression is increased in tubular cells and/or glomerular podocytes and parietal 
cells in human metabolic nephropathies, polycystic kidney disease, graft rejection 
and kidney cancer and in experimental diabetic nephropathy and glomerulonephritis. 
Stressors like abnormal metabolite (glucose, lyso-Gb3) levels and inflammatory cyto-
kines increase kidney cell CD74. MIF activates CD74 to increase inflammatory cytokines 
in podocytes and tubular cells and proliferation in glomerular parietal epithelial cells and 
cyst cells. MIF overexpression promotes while MIF targeting protects from experimental 
glomerular injury and kidney cysts, and interference with MIF/CD74 signaling or CD74 
deficiency protected from crescentic glomerulonephritis. However, CD74 may protect 
from interstitial kidney fibrosis. Furthermore, CD74 expression by stressed kidney cells 
raises questions about the kidney safety of cancer therapy strategies delivering lethal 
immunoconjugates to CD74-expressing cells. Thus, understanding CD74 biology in 
kidney cells is relevant for kidney therapeutics.
Keywords: kidney, CD74, d-dopachrome tautomerase (d-DT/MiF-2), macrophage inhibitory factor, inflammation, 
Fabry, diabetes, polycystic kidney disease
CD74
CD74 (MHC class II invariant chain, Ii) is a transmembrane glycoprotein that regulates protein 
trafficking and is a cell surface receptor for the cytokines macrophage migration inhibitory factor 
(MIF) and d-dopachrome tautomerase (d-DT/MIF-2) (1). During kidney injury, leukocytes and 
intrinsic renal cells express CD74 (2). In the kidneys, MIF promotes experimental glomerular injury 
and cystogenesis, while recent reports suggest a protective role in interstitial fibrosis (2–4). However, 
CD74 is a multifunctional protein. Thus, the consequences of therapeutically targeting CD74 may 
differ from the consequences of targeting MIF. We, now, summarize the function of CD74 and review 
its expression and role in kidney injury, highlighting open questions. The detailed description of the 
role of CD74 in the immune system is beyond the scope of this review.
CD74 Functions
CD74 regulates intracellular trafficking and functions as a chaperone and a cell membrane receptor, 
modulating B, T, and dendritic cell responses (1, 5) and promoting tumor growth by increasing 
tumor cell survival or proliferation. Thus, CD74 is considered a therapeutic target in malignancy. 
In addition, CD74 regulates proliferation, survival, and secretion of inflammatory and fibrosis 
mediators in non-immune and non-tumor cells (1, 2). Thus, CD74 may modulate tissue injury and 
homeostasis beyond its effect on immune regulation.
September 2015 | Volume 6 | Article 4832
Valiño-Rivas et al. CD74 and the kidney
Frontiers in Immunology | www.frontiersin.org
Protein Trafficking
CD74 interacts with MHC class I and II proteins, contributing 
to antigen presentation. CD74 directs transport of MHC class II 
α and β chains from the endoplasmic reticulum (ER) or the cell 
surface to endosomes (6). As a chaperone, CD74 contributes to 
peptide editing in the MHC class II compartment. In endosomes, 
proteases degrade CD74, releasing MHC class II molecules. 
Prevention of CD74 degradation promotes the cell surface locali-
zation of MHC II. Extracellular CD74/cathepsin L complexes 
are found in human kidneys (1, 7, 8). CD74 also associates with 
angiotensin II type I receptors (AT1), leading to AT1 proteasomal 
degradation (9).
Cell Surface Receptor
Only a small amount of CD74 (2–5%) is expressed at the cell sur-
face (10, 11). Cell surface CD74 is a receptor for MIF and MIF-2. 
CD74 lacks signaling motifs, but may generate fragments with 
transcription factor activity and binds to signaling proteins, such 
as CD44. Ligand binding to CD74 leads to CD74 phosphoryla-
tion, endocytosis, regulated intramembrane proteolysis (RIP), 
and release of CD74 intracellular domain (CD74-ICD) into the 
cytosol that translocates to the nucleus and activates NF-κB (10, 
12–14). RIP might occur in cultured vascular smooth muscle 
cells since γ-secretase activity was required for MCP-1 expres-
sion induced by activating anti-CD74 antibodies. However, the 
pathophysiological implications remain unclear since MIF did 
not increase MCP-1 in these cells (15).
Migration inhibitory factor trimers activate CD74, and CD74 
alone is required for MIF binding (16). In addition, MIF can also 
engage chemokine receptors CXCR2, CXCR4, and CXCR7 (10, 
17). Cells that express two receptors, e.g., CD74 and CXCR2, may 
be more responsive to MIF (17). MIF-induced CD74 signaling 
complexes with CXCR2, CXCR4, or CXCR7 promote chemokine 
expression and chemotaxis (17–19). CD44 is the signaling com-
ponent of the MIF-CD74 receptor complex and recruits the Src 
tyrosine kinase to activate ERK1/2 in macrophages and Syk, Akt, 
and NFκB in B cells (20, 21). Thus, the receptor complex activates 
kinase cascades and transcription factors. Interestingly MIF, itself 
increases CD44 expression (22).
Migration inhibitory factor-2 is 30% homologous to MIF, also 
activates CD74 (23, 24) and is responsible for residual CD74-
dependent chemotactic activity in MIF−/− mice (17). MIF-2 
binding to CD74/CD44 activates kinases, downstream proin-
flammatory pathways, and β-catenin (25). However, MIF-2 lacks 
the pseudo(E)LR motif present in MIF that mediates interaction 
with CXCR2 and CXCR4, and thus, it is a more selective CD74 
agonist than MIF. Circulating MIF-2 levels correlate with sever-
ity of sepsis, a cause of acute kidney injury, and MIF or MIF-2 
blockade reduced systemic inflammation, protecting mice from 
lethal endotoxemia.
Migration inhibitory factor or MIF-2 activation of CD74 
regulates cell survival and proliferation of B cells (21) and epi-
thelial cells, including gastric epithelial cells and type II alveolar 
epithelial cells (26, 27). MIF or MIF-2 binding to CD74 protects 
the heart and liver from injury, including from ischemia–reper-
fusion (28–30). In the heart, CD74 promotes phosphorylation 
of the AMPK catalytic alpha subunit in response to increased 
intracellular calcium and activation of Ca2+/calmodulin-activated 
kinase kinase-2 (CaMKK-2) (29). Interestingly, liver expression of 
CD74 protected mice from lethality induced by agonistic anti-Fas 
antibodies as CD74 interfered with immediate early steps in Fas 
signaling at the plasma membrane, and the anti-CD74 antibody 
milatuzumab sensitized BJAB cells to Fas-mediated apoptosis 
(31). Fas ligand and Fas have long been known to promote 
kidney injury (32). In fact, agonistic anti-Fas antibodies induced 
glomerular cell apoptosis in vivo (33). Thus, CD74 interference 
with Fas signaling should be explored in kidney cells. The MIF/
CD74/AMPK pathway also protects hepatocytes in metabolic 
liver injury, such as non-alcoholic steatohepatitis (30). In this 
regard, liver fibrosis was increased in MIF−/− or CD74−/− mice 
suggesting an antifibrotic effect of MIF/CD74 (34). Enhanced 
fibrosis was thought to result from the release of MIF inhibition 
of PDGF-induced migration and proliferation of hepatic stel-
late cells. MIF/CD74 also protects the lungs. Both MIF−/− and 
CD74−/− mice developed spontaneous emphysema by 6 months 
of age (35). However, CD74 may also contribute to disease, as 
discussed below for glomerulonephritis and kidney cysts. In this 
regard, CD74 deficiency reduced atherosclerosis in low-density 
lipoprotein receptor-deficient LDLR−/− mice (36) and protected 
NOD mice from development of diabetes, probably by enhancing 
T regulatory cell number and impairing antigen presentation (37).
Among kidney cells, MIF induced proliferation in parietal epi-
thelial cells but not in podocytes (4) (Figure 1). Absence of CD44 
or the terminal differentiation state of podocytes may account for 
the differences. MIF, MIF-2, CD74, and CD44 promote clear cell 
renal cell carcinoma, cell proliferation, and HIF-activation (38, 
39). While MIF and MIF-2 overlap in controlling cell survival 
and tumor formation, MIF-2 plays a dominant role in renal 
cancer tumor growth in  vivo (40). MIF also confers resistance 
to senescence and cell death in mesenchymal stem cells through 
CD74-dependent AMPK-FOXO3a signaling and c-Met activa-
tion (41).
In renal tubular epithelial cells and podocytes, MIF binding 
to CD74 leads to persistent activation of p38 and ERK1/2 MAPK 
and expression of inflammatory mediators (e.g., TRAIL and 
MCP-1) (11, 42). MIF upregulation of inflammatory mediators 
was a late event, observed at 24 h (11). Thus, it was delayed as 
compared to responses elicited by the inflammatory cytokines 
TNF or TWEAK or metabolites, such as lyso-Gb3 (43, 44).
In summary, MIF-2 and MIF have an overlapping spectrum 
of activities mediated by CD74 activation and may cooperate, 
additively inducing chemokine secretion or survival in non-renal 
cells and proliferation in kidney cancer cells (45).
Regulation of CD74 expression
CD74 expression is increased during tissue injury in diverse 
organs and in malignancies, including kidney cancer (2, 15, 28, 
34, 46–48). There is limited information on the regulation of 
CD74 expression in renal cells. In normal mouse and human 
kidneys, tubular but not glomerular epithelium expresses low 
levels of CD74 (4, 11). By contrast, cultured human podocytes 
and proximal tubular cells and murine glomerular parietal 
epithelial cells express CD74 (4, 11). Abnormally high concen-
trations of certain metabolites (e.g., glucose and lyso-Gb3) and 
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inflammatory cytokines, such as TNF, increase CD74 expression 
in podocytes and/or tubular cells (11, 49). IFN-γ increases CD74 
expression in vivo in kidney tubular epithelium and in endothelial 
cells of larger kidney vessels (50). The factors known to upregulate 
CD74 expression in kidney cells may be relevant for diabetic 
nephropathy, Fabry disease, and inflammatory conditions.
Regulation of CD74 interaction with MiF
Endogenous factors or drugs interfere with MIF binding to 
CD74 or downregulate CD74 expression and a better under-
standing of these interactions may provide therapeutic tools to 
manipulate the system. Some agents targeting MIF prevent MIF 
binding to CD74. These include antibodies, RPS19 (ribosomal 
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FiGURe 1 | CD74 functions in renal cells. Glomerular parietal epithelial cells express CD44 when activated and it is thought that CD44 contributes to the 
proliferative response. CD44 is not expressed by podocytes and its role of CD74 signaling in tubular cells has not been characterized. Thus, in tubular cells, CD44 is 
not depicted as part of the CD74 signaling complex. Cells expressing CXCR2, CXCR4, and CXCR7 are also indicated, although these receptors are depicted away 
from MIF when in that specific cell type, there is no information on their involvement in MIF signaling. In tubular epithelium with genetic defects in PKD1, MIF 
promotes tubular cell proliferation and cystogenesis and a CD74 antibody blocked the MIF-induced phosphorylation of ERK but not inflammatory responses.
protein S19), a component of the 40S small ribosomal subunit 
that binds MIF and behaves as an endogenous blocker of MIF 
binding to CD74 (51) and the small molecule MIF antagonist 
3-(3-hydroxybenzyl)-5-methylbenzooxazol-2-one (MIF098) that 
decreases tautomerase activity and MIF-CD74 binding. MIF098 
attenuated MIF-dependent ERK1/2 phosphorylation in human 
synovial fibroblasts (52) and promoted hyperoxia-induced lung 
injury in vivo (53), supporting the tissue-protective properties of 
MIF/CD74. Other compounds bind to CD74 or interfere with 
CD74 processing. The HLA-DRα1 domain binds to and down-
regulates CD74 on monocytes, directly inhibiting MIF binding to 
CD74 and blocking downstream inflammation in murine auto-
immune encephalomyelitis. Adding a peptide extension [myelin 
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oligodendrocyte glycoprotein (MOG)-35–55 peptide] that 
modified the secondary structure, enhanced the potency of the 
DRα1 domain in downregulating CD74 cell surface expression 
(54). Binding of partial MHC class II complexes comprised of 
linked β1α1 domains with covalently attached antigenic peptides 
[recombinant T-cell receptor ligands (RTLs)] to CD74 blocks 
the accessibility and availability of CD74 for MIF binding and 
downstream inflammation in monocytes (55).
The intramembrane protease presenilin homolog signal-pep-
tide-peptidase-like 2a (SPPL2a) cleaves CD74. SPPL2a−/− mice 
accumulate N-terminal fragments of CD74 that impair membrane 
traffic within the endocytic system and alter B cell biology (56, 
57). Since in SPPL2a−/− mice, CD74 signaling is inhibited, SPPL2a 
inhibitors may offer new pathways to inhibit CD74 signaling (58). 
Despite these recent advances, there is little or no information 
on the potential therapeutic or adverse effects of CD74 targeting 
strategies for kidney diseases and the available information is 
mainly derived from the study of CD74−/− mice, which may have 
developed adaptive mechanisms over development.
The role of soluble CD74 is unclear. Circulating soluble CD74 
with MIF neutralizing activity was increased in primary biliary 
cirrhosis and was hypothesized to contribute to liver fibrosis (59). 
Indeed, soluble CD74 ectodomain prevents binding of MIF to 
cell surface receptors (10). However, MIF/sCD74 complexes were 
found to enhance MIF antioxidant activity (60). Autoantibodies 
against CD74 (anti-HLA class II-associated invariant chain pep-
tide, CLIP) were found in 67% of ankylosing spondylitis patients, 
in 15% of systemic lupus erythematosus patients, and only in 
0.8% of blood donors (61, 62).
CD74 and Kidney injury
There is a growing body of evidence linking CD74 to promotion 
or protection from kidney injury (Figure 2).
FiGURe 2 | CD74 in kidney disease. Studies in CD74-deficient mice with kidney disease have only been published in abstract form. Thus, potential roles of CD74 
in kidney disease have been mainly derived from abstracts or studies in which MIF was targeted in cultured cells or experimental animals. A putative effect of CD74 
targeting on glomerular injury is only hypothetical and based on studies in which MIF was targeted. In polycystic kidney disease, MIF promotes cystogenesis. The 
role of CD74 is unclear, but CD74 expression is increased in cystic epithelium.
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expression of CD74 and Related Molecules in 
Kidney injury
MIF has long been known to be upregulated in kidney injury (2). 
However, reports of increased CD74 expression are more recent 
and there is very little information on MIF-2.
Low CD74 expression may limit inflammatory and prolif-
erative cell responses to MIF, and the increased renal cell CD74 
expression observed during kidney injury (discussed below) may 
contribute, together with increased ligand availability, to elicit 
biological responses during kidney disease. Thus, overexpression 
of CD74 led to upregulation of NF-κB-dependent genes encod-
ing cytokines in macrophages (63) and to NFκB activation and 
proliferation in human embryonic kidney cells (64).
CD74 is upregulated in tubular epithelial cells in at least some 
forms of chronic kidney disease (CKD), such as kidney graft 
rejection, diabetic and Fabry nephropathy and autosomal domi-
nant polycystic kidney disease (ADPKD), and in podocytes in 
human diabetic nephropathy and Fabry nephropathy (11, 65, 66). 
A transcriptomics analysis also revealed increased kidney CD74 
mRNA expression in human hypertensive nephropathy (11). 
CD74 is also increased in human clear cell renal cell carcinoma 
(67), in B cells, and kidney of lupus mice in parallel to progression 
of inflammation (68) and in the tubulointerstitium in anti-GBM 
nephritis, where it was expressed de novo in glomerular parietal 
epithelial cells and crescents (51). Interestingly, kidney cancer 
may be a complication of CKD-related acquired polycystic kidney 
disease (69). There is much less information on the expression of 
CD74 in acute kidney injury.
Migration inhibitory factor was recently identified as an impor-
tant regulator of cyst growth and therapeutic target in ADPKD (3). 
MIF accumulated in cyst fluid of human ADPKD, promoted cystic 
epithelial cell proliferation and regulated apoptosis. In experimen-
tal murine polycystic kidney disease, MIF was required for renal 
inflammation and cyst expansion. CD74 expression was increased 
in Pkd1 mutant renal epithelial cells and ADPKD kidneys, sug-
gesting that MIF actions may imply CD74 activation. However, a 
CD74 antibody blocked the MIF-induced phosphorylation of ERK 
but did not modulate the MIF-induced inflammatory response of 
increased MCP-1 expression in culture (3).
The CD74 signaling machinery may also be upregulated in 
kidney disease. CD44 is rapidly upregulated after injury in acute 
and chronic experimental and human kidney disease including 
glomerulonephritis, diabetic nephropathy, cyclosporine nephro-
toxicity, urate nephropathy, and ischemia–reperfusion kidney 
injury (70–76). Increased CD44 expression was localized to 
tubules, glomerular parietal epithelial cells, mesangial cells and 
infiltrating macrophages, T cells, and neutrophils (70, 72, 75–78).
Finally, the expression of at least some CD74 ligands is also 
increased in kidney injury. MIF expression is upregulated in 
acute and chronic, human, and experimental kidney diseases 
(2). However, there is no information on MIF-2 expression and 
kidney disease.
CD74 Targeting and Kidney injury
Neutralizing anti-MIF antibodies, small molecules or endog-
enous inhibitors or MIF−/− mice have shown that MIF aggravates 
anti-GBM glomerulonephritis (69–71), experimental IgAN 
(79), and lupus nephritis (80). More recently, the inhibitor of 
MIF/CD74 interactions RPS19 prevented the development of 
glomerular crescents, necrosis, inflammation, renal dysfunction, 
proteinuria, and the upregulation of MIF and CD74 in anti-GBM 
glomerulonephritis (51). However, MIF absence from mice 
did not protect from renal allograft rejection (81) or ureteral 
obstruction-induced kidney injury (82).
There is limited experimental and no clinical data on CD74 
targeting in kidney injury. Given the multiple MIF and CD74 
functions, studies are needed that explore whether targeting 
CD74 is therapeutic in models in which targeting MIF was ben-
eficial. Information on the role of CD74 as a potential therapeutic 
target in tissue injury is mainly derived from CD74−/− mice. As 
discussed above, CD74 deficiency may be beneficial for some 
non-renal diseases, such as liver and heart disease, and deleteri-
ous in others, such as vascular injury. Specifically, liver fibrosis 
was increased in CD74−/− mice (34). An initial report found no 
protection from ureteral obstruction-induced kidney inflamma-
tion or fibrosis (82), but an abstract indicated that MIF target-
ing promoted interstitial fibrosis and inflammation following 
ureteral obstruction, whereas recombinant MIF reduced fibrosis 
(4). According to abstract reports, CD74 deficiency was also 
associated with increased interstitial fibrosis and inflammation 
following ureteral obstruction (day 5) and ischemia–reperfu-
sion (day 21) (4). By contrast, CD74−/− mice are protected from 
glomerular injury induced by anti-GBM antiserum (Djudjaj 
JASN2015).
Since MIF or MIF-2 activation of CD74 is tissue protective in 
heart ischemia and liver injury induced by activation of the Fas 
receptor or metabolic disorders, a similar protective effect maybe 
hypothesized in ischemic acute kidney injury or metabolic kidney 
diseases characterized by increased CD74 expression, such as dia-
betic nephropathy or Fabry disease. Interventional studies should 
test these hypotheses and evaluate whether changes in fibrosis 
after kidney ischemia–reperfusion is secondary to an improved 
initial kidney injury or to a specific action of fibrosis mechanisms. 
These studies should differentiate between complete abrogation 
of CD74 expression (CD74−/−) and therapeutic downregulation 
of CD74. Incomplete blockade of the system may have different 
consequences than complete CD74 absence, given the potential 
proinflammatory effects of excess CD74 activation.
Kidney Safety of Lethal Anti-CD74 
immunoconjugates
The anti-CD74 antibody hLL1 milatuzumab, alone or as an 
immunoconjugate, is undergoing clinical trials to treat malig-
nancy (83, 84). Milatuzumab binds to CD74 and promotes 
internalization of the antibody-CD74 complex, thus delivering 
conjugated antitumoral agents inside tumor cells with high 
CD74 expression, but not to normal cells with low CD74 levels 
(85). Since CD74 expression is also increased in renal cells from 
injured kidneys, nephrotoxicity is a potential complication of 
antitumoral anti-CD74 therapy, especially in patients with prior 
kidney disease since the active chemotherapeutic agent may be 
released inside already injured, CD74-expressing renal cells. This 
may be of special concern for one of the indications under study, 
multiple myeloma, which frequently causes kidney disease.
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Summary and Conclusions
The role of CD74 in kidney injury has barely been explored and 
the scarce information available is derived from CD74-deficient 
mice that may not recapitulate the findings of targeting CD74 
de novo in an adult. CD74 may contribute to or protect from 
tissue injury in a disease-specific manner. Thus, like MIF, CD74 
may protect from experimental kidney interstitial fibrosis 
but promotes glomerular injury, while MIF (and potentially 
CD74) also promotes polycystic kidney disease. A few years 
ago, the situation was less complex. Given the longstanding 
preclinical evidence for a pathogenic role of MIF in glomerular 
kidney disease, anti-MIF strategies were tested in renal disease, 
although the sponsor decided to terminate a phase 1 trial of the 
anti-MIF monoclonal antibody imalumab in lupus nephritis 
(NCT01541670). However, MIF, MIF-2, and CD74 may be tissue 
protective or promote injury in an organ- and disease-specific 
manner and different forms of therapeutic manipulation of the 
system may be envisioned for different indications, from inhibit-
ing to actually activating CD74 signaling. The potential impact 
of future intervention on CD74 for kidney disease is double. On 
one hand, therapeutic modulation of the system may be used to 
treat kidney disease. On the other, the kidney may suffer adverse 
effects from the therapeutic targeting on non-kidney diseases. 
Therapeutic approaches blocking MIF or CD74 signaling for 
non-renal indications may theoretically promote kidney fibrosis 
as an adverse effect, while therapeutic approaches activating 
the system may cause or aggravate glomerular injury. Thus, a 
better understanding of CD74 and the kidney is required for 
nephrologists and non-nephrologists. Future areas of research 
include the potential therapeutic interest of molecules aimed 
at increasing or decreasing CD74 activity for different forms of 
kidney disease, including acute and chronic kidney injury, the 
potential renal adverse effects of these approaches when used for 
non-renal indications, the impact on kidney disease of naturally 
occurring circulating soluble CD74 or CLIP and the kidney 
safety of antitumor therapeutic strategies delivering toxins into 
CD74-expressing cells or targeting CD74. Additional unknowns 
to be solved include the drivers and consequences of CD74 RIP 
in kidney cells, the significance for kidney disease of MIF-2 and 
of CD74 actions on mesenchymal stem cells, and whether AMPK 
is activated by CD74 in renal cells since, contrary to the heart, no 
difference in AMPK activation by acute ischemia was observed 
between MIF−/− and wild-type mice in the kidney, and this was 
attributed to lower CD74 expression in the kidney (86).
Acknowledgments
Grant support: ISCIII and FEDER funds CP14/00133, 
PI13/00047, Sociedad Española de Nefrologia, ISCIII-RETIC 
REDinREN/RD012/0021, Comunidad de Madrid CIFRA S2010/
BMD-2378. Salary support: FIS to LV-R, Miguel Servet to MS-N. 
Programa Intensificación Actividad Investigadora (ISCIII/
Agencia Laín-Entralgo/CM) to AO.
September 2015 | Volume 6 | Article 4837
Valiño-Rivas et al. CD74 and the kidney
Frontiers in Immunology | www.frontiersin.org
 20. Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling compo-
nent of the macrophage migration inhibitory factor-CD74 receptor complex. 
Immunity (2006) 25:595–606. doi:10.1016/j.immuni.2006.08.020 
 21. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, 
et al. Macrophage migration inhibitory factor induces B cell survival by acti-
vation of a CD74-CD44 receptor complex. J Biol Chem (2008) 283:2784–92. 
doi:10.1074/jbc.M703265200 
 22. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, van EM, 
et al. MIF deficiency reduces chronic inflammation in white adipose tissue 
and impairs the development of insulin resistance, glucose intolerance, and 
associated atherosclerotic disease. Circ Res (2009) 105:99–107. doi:10.1161/
CIRCRESAHA.109.199166 
 23. Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, et al. The D-dopachrome 
tautomerase (DDT) gene product is a cytokine and functional homolog of 
macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A 
(2011) 108:E577–85. doi:10.1073/pnas.1102941108 
 24. Merk M, Mitchell RA, Endres S, Bucala R. D-dopachrome tautomerase (D-DT 
or MIF-2): doubling the MIF cytokine family. Cytokine (2012) 59:10–7. 
doi:10.1016/j.cyto.2012.03.014 
 25. Xin D, Rendon BE, Zhao M, Winner M, McGhee CA, Mitchell RA. The MIF 
homologue D-dopachrome tautomerase promotes COX-2 expression through 
beta-catenin-dependent and -independent mechanisms. Mol Cancer Res 
(2010) 8:1601–9. doi:10.1158/1541-7786.MCR-10-0101 
 26. Beswick EJ I, Pinchuk V, Suarez G, Sierra JC, Reyes VE. Helicobacter pylori 
CagA-dependent macrophage migration inhibitory factor produced by 
gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. 
J Immunol (2006) 176:6794–801. doi:10.4049/jimmunol.176.11.6794 
 27. Marsh LM, Cakarova L, Kwapiszewska G, von WW, Herold S, Seeger W, et al. 
Surface expression of CD74 by type II alveolar epithelial cells: a potential 
mechanism for macrophage migration inhibitory factor-induced epithelial 
repair. Am J Physiol Lung Cell Mol Physiol (2009) 296:L442–52. doi:10.1152/
ajplung.00525.2007 
 28. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al. Macrophage 
migration inhibitory factor stimulates AMP-activated protein kinase in the 
ischaemic heart. Nature (2008) 451:578–82. doi:10.1038/nature06504 
 29. Qi D, Atsina K, Qu L, Hu X, Wu X, Xu B, et  al. The vestigial enzyme 
D-dopachrome tautomerase protects the heart against ischemic injury. J Clin 
Invest (2014) 124:3540–50. doi:10.1172/JCI73061 
 30. Heinrichs D, Berres ML, Coeuru M, Knauel M, Nellen A, Fischer P, et  al. 
Protective role of macrophage migration inhibitory factor in nonalcoholic 
steatohepatitis. FASEB J (2014) 28:5136–47. doi:10.1096/fj.14-256776 
 31. Berkova Z, Wang S, Ao X, Wise JF, Braun FK, Rezaeian AH, et al. CD74 inter-
feres with the expression of fas receptor on the surface of lymphoma cells. J 
Exp Clin Cancer Res (2014) 33:80. doi:10.1186/s13046-014-0080-y 
 32. Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renal injury. Nephrol 
Dial Transplant (1999) 14:1831–4. doi:10.1093/ndt/14.8.1831 
 33. Gonzalez-Cuadrado S, Lorz C, Garcia del MR, O’alle F, Alonso C, Ramiro F, 
et al. Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice 
in vivo. Kidney Int (1997) 51:1739–46. doi:10.1038/ki.1997.239 
 34. Heinrichs D, Knauel M, Offermanns C, Berres ML, Nellen A, Leng L, et al. 
Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects 
in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A (2011) 
108:17444–9. doi:10.1073/pnas.1107023108 
 35. Sauler M, Leng L, Trentalange M, Haslip M, Shan P, Piecychna M, et  al. 
Macrophage migration inhibitory factor deficiency in chronic obstructive 
pulmonary disease. Am J Physiol Lung Cell Mol Physiol (2014) 306:L487–96. 
doi:10.1152/ajplung.00284.2013 
 36. Sun J, Hartvigsen K, Chou MY, Zhang Y, Sukhova GK, Zhang J, 
et  al. Deficiency of antigen-presenting cell invariant chain reduces 
atherosclerosis in mice. Circulation (2010) 122:808–20. doi:10.1161/
CIRCULATIONAHA.109.891887 
 37. Mellanby RJ, Koonce CH, Monti A, Phillips JM, Cooke A, Bikoff EK. Loss 
of invariant chain protects nonobese diabetic mice against type 1 diabetes. 
J Immunol (2006) 177:7588–98. doi:10.4049/jimmunol.177.11.7588 
 38. Ji SQ, Su XL, Cheng WL, Zhang HJ, Zhao YQ, Han ZX. Down-regulation 
of CD74 inhibits growth and invasion in clear cell renal cell carcinoma 
through HIF-1alpha pathway. Urol Oncol (2014) 32:153–61. doi:10.1016/j.
urolonc.2012.09.013 
 39. Du W, Wright BM, Li X, Finke J, Rini BI, Zhou M, et al. Tumor-derived mac-
rophage migration inhibitory factor promotes an autocrine loop that enhances 
renal cell carcinoma. Oncogene (2013) 32:1469–74. doi:10.1038/onc.2012.143 
 40. Pasupuleti V, Du W, Gupta Y I, Yeh J, Montano M, Magi-Galuzzi C, et  al. 
Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-depen-
dent gene, cooperates with macrophage migration inhibitory factor in renal 
tumorigenesis. J Biol Chem (2014) 289:3713–23. doi:10.1074/jbc.M113.500694 
 41. Xia W, Zhang F, Xie C, Jiang M, Hou M. Macrophage migration inhibitory 
factor confers resistance to senescence through CD74-dependent AMPK-
FOXO3a signaling in mesenchymal stem cells. Stem Cell Res Ther (2015) 6:82. 
doi:10.1186/s13287-015-0076-3 
 42. Lorz C, Benito-Martin A, Boucherot A, Ucero AC, Rastaldi MP, Henger A, 
et  al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 
(2008) 19:904–14. doi:10.1681/ASN.2007050581 
 43. Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler 
M, et al. The cytokine TWEAK modulates renal tubulointerstitial inflamma-
tion. J Am Soc Nephrol (2008) 19:695–703. doi:10.1681/ASN.2007050577 
 44. Sanchez-Nino MD, Poveda J, Sanz AB, Carrasco S, Ruiz-Ortega M, Selgas R, 
et al. 3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. Arch 
Toxicol (2014) 88:597–608. doi:10.1007/s00204-013-1181-7 
 45. Coleman AM, Rendon BE, Zhao M, Qian MW, Bucala R, Xin D, et  al. 
Cooperative regulation of non-small cell lung carcinoma angiogenic potential 
by macrophage migration inhibitory factor and its homolog, D-dopachrome 
tautomerase. J Immunol (2008) 181:2330–7. doi:10.4049/jimmunol.181.4.2330 
 46. Beswick EJ, Das S I, Pinchuk V, Adegboyega P, Suarez G, Yamaoka Y, et al. 
Helicobacter pylori-induced IL-8 production by gastric epithelial cells 
up-regulates CD74 expression. J Immunol (2005) 175:171–6. doi:10.4049/
jimmunol.175.1.171 
 47. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, et al. CD74 is 
expressed by multiple myeloma and is a promising target for therapy. Clin 
Cancer Res (2004) 10:6606–11. doi:10.1158/1078-0432.CCR-04-0182 
 48. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’ disease: 
distinctive gene expression profiles and novel susceptibility candidate genes. 
Hum Mol Genet (2001) 10:445–56. doi:10.1093/hmg/10.5.445 
 49. Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, 
Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular 
podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 
(2011) 26:1797–802. doi:10.1093/ndt/gfq306 
 50. Momburg F, Koch N, Moller P, Moldenhauer G, Butcher GW, Hammerling GJ. 
Differential expression of Ia and Ia-associated invariant chain in mouse tissues 
after in vivo treatment with IFN-gamma. J Immunol (1986) 136:940–8. 
 51. Lv J, Huang XR, Klug J, Frohlich S, Lacher P, Xu A, et al. Ribosomal protein S19 
is a novel therapeutic agent in inflammatory kidney disease. Clin Sci (Lond) 
(2013) 124:627–37. doi:10.1042/CS20120526 
 52. Hare AA, Leng L, Gandavadi S, Du X, Cournia Z, Bucala R, et al. Optimization 
of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage 
migration inhibitory factor (MIF). Bioorg Med Chem Lett (2010) 20:5811–4. 
doi:10.1016/j.bmcl.2010.07.129 
 53. Sauler M, Zhang Y, Min JN, Leng L, Shan P, Roberts S, et al. Endothelial CD74 
mediates macrophage migration inhibitory factor protection in hyperoxic 
lung injury. FASEB J (2015) 29:1940–9. doi:10.1096/fj.14-260299 
 54. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, et al. 
HLA-DRalpha1 constructs block CD74 expression and MIF effects in exper-
imental autoimmune encephalomyelitis. J Immunol (2014) 192:4164–73. 
doi:10.4049/jimmunol.1303118 
 55. Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows GG, Bourdette D, 
et al. Partial MHC class II constructs inhibit MIF/CD74 binding and down-
stream effects. Eur J Immunol (2013) 43:1309–21. doi:10.1002/eji.201243162 
 56. Schneppenheim J, Dressel R, Huttl S, Lullmann-Rauch R, Engelke M, Dittmann 
K, et al. The intramembrane protease SPPL2a promotes B cell development 
and controls endosomal traffic by cleavage of the invariant chain. J Exp Med 
(2013) 210:41–58. doi:10.1084/jem.20121069 
 57. Beisner DR, Langerak P, Parker AE, Dahlberg C, Otero FJ, Sutton SE, et al. The 
intramembrane protease Sppl2a is required for B cell and DC development 
and survival via cleavage of the invariant chain. J Exp Med (2013) 210:23–30. 
doi:10.1084/jem.20121072 
 58. Ran Y, Ladd GZ, Ceballos-Diaz C, Jung JI, Greenbaum D, Felsenstein KM, 
et al. Differential inhibition of signal peptide peptidase family members by 
September 2015 | Volume 6 | Article 4838
Valiño-Rivas et al. CD74 and the kidney
Frontiers in Immunology | www.frontiersin.org
established gamma-secretase inhibitors. PLoS One (2015) 10:e0128619. 
doi:10.1371/journal.pone.0128619 
 59. Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, et al. The role of mac-
rophage migration inhibitory factor in autoimmune liver disease. Hepatology 
(2014) 59:580–91. doi:10.1002/hep.26664 
 60. Stoppe C, Rex S, Goetzenich A, Kraemer S, Emontzpohl C, Soppert J, et al. 
Interaction of MIF family proteins in myocardial ischemia/reperfusion 
damage and their influence on clinical outcome of cardiac surgery patients. 
Antioxid Redox Signal (2015). doi:10.1089/ars.2014.6243 
 61. Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter 
S, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 
(2014) 73:1211–4. doi:10.1136/annrheumdis-2012-202208 
 62. Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J. High prevalence of 
anti-CD74 antibodies specific for the HLA class II-associated invariant chain 
peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis (2014) 
73:1079–82. doi:10.1136/annrheumdis-2012-202177 
 63. Zhang H, Liu C, Cheng S, Wang X, Li W, Charreyre C, et al. Porcine CD74 
is involved in the inflammatory response activated by nuclear factor kappa 
B during porcine circovirus type 2 (PCV-2) infection. Arch Virol (2013) 
158:2285–95. doi:10.1007/s00705-013-1750-3 
 64. Liu YH, Lin CY, Lin WC, Tang SW, Lai MK, Lin JY. Up-regulation of vascular 
endothelial growth factor-D expression in clear cell renal cell carcinoma 
by CD74: a critical role in cancer cell tumorigenesis. J Immunol (2008) 
181:6584–94. doi:10.4049/jimmunol.181.9.6584 
 65. Saleem M, Sawyer GJ, Schofield RA, Seymour ND, Gustafsson K, Fabre 
JW. Discordant expression of major histocompatibility complex class II 
antigens and invariant chain in interstitial dendritic cells. Implications 
for self-tolerance and immunity. Transplantation (1997) 63:1134–8. 
doi:10.1097/00007890-199704270-00013 
 66. Pagni F, Pieruzzi F, Zannella S, Di GA, Bovo G, Ferrario F, et  al. Possible 
pathogenetic relationship between Fabry disease and renal cell carcinoma. 
Am J Nephrol (2012) 36:537–41. doi:10.1159/000345465 
 67. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, et  al. 
Expression profiling of renal epithelial neoplasms: a method for tumor clas-
sification and discovery of diagnostic molecular markers. Am J Pathol (2001) 
158:1639–51. doi:10.1016/S0002-9440(10)64120-X 
 68. Lapter S, Ben-David H, Sharabi A, Zinger H, Telerman A, Gordin M, 
et  al. A role for the B-cell CD74/macrophage migration inhibitory factor 
pathway in the immunomodulation of systemic lupus erythematosus 
by a therapeutic tolerogenic peptide. Immunology (2011) 132:87–95. 
doi:10.1111/j.1365-2567.2010.03342.x 
 69. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J 
Am Soc Nephrol (2009) 4:1998–2007. doi:10.2215/CJN.02020309 
 70. Florquin S, Nunziata R, Claessen N, van den Berg FM, Pals ST, Weening JJ. 
CD44 expression in IgA nephropathy. Am J Kidney Dis (2002) 39:407–14. 
doi:10.1053/ajkd.2002.30563 
 71. Han DH, Song HK, Lee SY, Song JH, Piao SG, Yoon HE, et al. Upregulation 
of hyaluronan and its binding receptors in an experimental model of 
chronic cyclosporine nephropathy. Nephrology (Carlton) (2010) 15:216–24. 
doi:10.1111/j.1440-1797.2009.01167.x 
 72. Kocak B, Orug T, Turhan N, Ozcay N, Gonenc F. CD44 expression in renal 
ischemia-reperfusion injury in rats. Int Urol Nephrol (2009) 41:791–4. 
doi:10.1007/s11255-009-9542-0 
 73. Okada A, Yasui T, Fujii Y, Niimi K, Hamamoto S, Hirose M, et al. Renal mac-
rophage migration and crystal phagocytosis via inflammatory-related gene 
expression during kidney stone formation and elimination in mice: detection 
by association analysis of stone-related gene expression and microstructural 
observation. J Bone Miner Res (2010) 25:2701–11. doi:10.1002/jbmr.158 
 74. Rouschop KM, Claessen N, Pals ST, Weening JJ, Florquin S. CD44 disruption 
prevents degeneration of the capillary network in obstructive nephropathy 
via reduction of TGF-beta1-induced apoptosis. J Am Soc Nephrol (2006) 
17:746–53. doi:10.1681/ASN.2005080808 
 75. Smeets B, Uhlig S, Fuss A, Mooren F, Wetzels JF, Floege J, et al. Tracing the 
origin of glomerular extracapillary lesions from parietal epithelial cells. J Am 
Soc Nephrol (2009) 20:2604–15. doi:10.1681/ASN.2009010122 
 76. Yang L, Brozovic S, Xu J, Long Y, Kralik PM, Waigel S, et al. Inflammatory gene 
expression in OVE26 diabetic kidney during the development of nephropathy. 
Nephron Exp Nephrol (2011) 119:e8–20. doi:10.1159/000324407 
 77. Nikolic-Paterson DJ, Jun Z, Tesch GH, Lan HY, Foti R, Atkins RC. De novo 
CD44 expression by proliferating mesangial cells in rat anti-Thy-1 nephritis. J 
Am Soc Nephrol (1996) 7:1006–14. 
 78. Sicking EM, Fuss A, Uhlig S, Jirak P, Dijkman H, Wetzels J, et al. Subtotal abla-
tion of parietal epithelial cells induces crescent formation. J Am Soc Nephrol 
(2012) 23:629–40. doi:10.1681/ASN.2011050449 
 79. Leung JC, Chan LY, Tsang AW, Liu EW, Lam MF, Tang SC, et  al. Anti-
macrophage migration inhibitory factor reduces transforming growth 
factor-beta 1 expression in experimental IgA nephropathy. Nephrol Dial 
Transplant (2004) 19:1976–85. doi:10.1093/ndt/gfh323 
 80. Hoi AY, Hickey MJ, Hall P, Yamana J, O’ullivan KM, Santos LL, et  al. 
Macrophage migration inhibitory factor deficiency attenuates macrophage 
recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 
(2006) 177:5687–96. doi:10.4049/jimmunol.177.8.5687 
 81. Jose MD, David JR, Atkins RC, Chadban SJ. Blockade of macrophage migra-
tion inhibitory factor does not prevent acute renal allograft rejection. Am J 
Transplant (2003) 3:1099–106. doi:10.1034/j.1600-6143.2003.00188.x 
 82. Rice EK, Nikolic-Paterson DJ, David JR, Bucala R, Metz CN, Atkins RC, et al. 
Macrophage accumulation and renal fibrosis are independent of macrophage 
migration inhibitory factor in mouse obstructive nephropathy. Nephrology 
(Carlton) (2004) 9:278–87. doi:10.1111/j.1440-1797.2004.00319.x 
 83. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A I, Horak D, et al. Antiproliferative 
activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell 
malignancies. Blood (2004) 104:3705–11. doi:10.1182/blood-2004-03-0890 
 84. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne 
H, et  al. Phase I, multicentre, dose-escalation trial of monotherapy with 
milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or 
refractory multiple myeloma. Br J Haematol (2013) 163:478–86. doi:10.1111/
bjh.12565 
 85. Martin P, Furman RR, Rutherford S, Ruan J, Ely S, Greenberg J, et al. Phase I 
study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients 
with previously treated B-cell lymphomas. Leuk Lymphoma (2015):1–21. doi:
10.3109/10428194.2014.1001987 
 86. Mount PF, Gleich K, Tam S, Fraser SA, Choy SW, Dwyer KM, et  al. The 
outcome of renal ischemia-reperfusion injury is unchanged in AMPK-beta1 
deficient mice. PLoS One (2012) 7:e29887. doi:10.1371/journal.pone.0029887 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Valiño-Rivas, Baeza-Bermejillo, Gonzalez-Lafuente, Sanz, Ortiz 
and Sanchez-Niño. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduc-
tion in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
